This company listing is no longer active
Jacobio Pharmaceuticals Group Future Growth
Future criteria checks 0/6
Jacobio Pharmaceuticals Group's revenue is forecast to decline at 24.8% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 41.1% |
| Revenue growth rate | -24.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 31 Jan 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 60 | N/A | N/A | N/A | 1 |
| 12/31/2024 | N/A | N/A | N/A | N/A | 1 |
| 12/31/2023 | 60 | N/A | N/A | N/A | 1 |
| 6/30/2023 | 81 | -410 | -449 | -400 | N/A |
| 3/31/2023 | 89 | -391 | -379 | -346 | N/A |
| 12/31/2022 | 96 | -372 | -309 | -292 | N/A |
| 9/30/2022 | 123 | -332 | -230 | -218 | N/A |
| 6/30/2022 | 150 | -292 | -151 | -145 | N/A |
| 3/31/2022 | 151 | -297 | -155 | -146 | N/A |
| 12/31/2021 | 153 | -301 | -159 | -147 | N/A |
| 9/30/2021 | 348 | -570 | -70 | -56 | N/A |
| 6/30/2021 | 544 | -839 | 18 | 36 | N/A |
| 3/31/2021 | 515 | -1,177 | 43 | 57 | N/A |
| 12/31/2020 | 486 | -1,514 | 68 | 79 | N/A |
| 9/30/2020 | 243 | -1,298 | -37 | -30 | N/A |
| 6/30/2020 | N/A | -1,082 | -141 | -139 | N/A |
| 3/31/2020 | N/A | -753 | -129 | -126 | N/A |
| 12/31/2019 | N/A | -425 | -116 | -113 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1167's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if 1167's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1167's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1167's revenue is expected to decline over the next 3 years (-24.8% per year).
High Growth Revenue: 1167's revenue is forecast to decline over the next 3 years (-24.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1167's Return on Equity is forecast to be high in 3 years time